Momenta Pharmaceuticals, Inc. (MNTA)

[t57]

TEVA says:

Copaxone® 20 mg/mL is expected to face two AB-rated generic competitors in the U.S. beginning in September 2015; earlier entry by generics could reduce operating income by $30 million to $50 million per month;